![](https://news.europawire.eu/wp-content/uploads/2013/12/novartis.jpg)
In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase … Read the full press release